News Sentiment

SNTI sentiment intelligence

Senti Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.44 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-57.6% over one week, -53.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

$Senti Biosciences (SNTI.US)$

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -57.6% Price reacting lower
Trend fit Trend inactive -53.1% over four weeks
Fair value -85.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 41
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 9
TradingView 8
TradingKey 5
Investing.com 3
MarketBeat 3
Moomoo 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 15
Deals and strategy 5
Analyst action 3
Guidance 2
Macro sensitivity 2
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
The Clinical Trial Vanguard Direct company coverage

Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy

Senti Bio is advancing its allogeneic CAR-NK program, SENTI-202, to a pivotal trial based on a "Donor X attribute" strategy that significantly improved response rates in heavily pretreated AML patients. This attribute, found in about 50% of adult donors and independently detectab

Tone
Positive 65/100
Event
Macro sensitivity
Published
18 May 2026 22:48
Source
The Clinical Trial Vanguard
The Globe and Mail Direct company coverage

Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure

Senti Biosciences, Inc. (SNTI) is facing significant refinancing and liquidity risks due to a costly note structure requiring a 200% cash payment at maturity or default. The company's inability to generate sufficient cash flow could lead to asset sales, dilutive equity raises, or

Tone
Negative 13/100
Event
Balance sheet
Published
17 May 2026 06:10
Source
The Globe and Mail
The Clinical Trial Vanguard Direct company coverage

Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML

Senti Biosciences gained FDA support for its SENTI-202 donor selection strategy in relapsed/refractory AML, based on post-hoc analysis showing a significant difference in remission rates depending on the NK cell donor. The company will now exclusively use "Donor X" derived cells

Tone
Positive 82/100
Event
Macro sensitivity
Published
15 May 2026 22:12
Source
The Clinical Trial Vanguard
Stock Titan Direct company coverage

Senti Bio (NASDAQ: SNTI) wins FDA RMAT backing and lines up $40M funding

Senti Biosciences (NASDAQ: SNTI) has reported a narrowed net loss and significant progress for its lead program, SENTI-202, including positive FDA Regenerative Medicine Advanced Therapy (RMAT) backing for a pivotal trial in relapsed/refractory AML. The company also secured a stra

Tone
Positive 71/100
Event
Market update
Published
15 May 2026 10:10
Source
Stock Titan